NCT03824795View on ClinicalTrials.gov

Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 7, 2019

Primary Completion Date

April 3, 2020

Study Completion Date

April 3, 2020

Conditions
Clostridium Difficile Infection
Interventions
DRUG

MGB-BP-3

MGB-BP-3

Trial Locations (9)

21401

Anne Arundel Medical Centre, Annapolis

22031

Verity Research Inc., Fairfax

32810

Omega Research Maitland LLC, Orlando

33155

Florida International Medical Research, Miami

59701

Mercury Street Medical Group PLLC, Butte

70121

Ochsner Clinic Foundation Infectious Disease Research, New Orleans

77084

Biopharma Informatic LLC, Houston

83404

Snake River Research PLLC, Idaho Falls

T2N 2T9

Foothills Medical Centre, Calgary

Sponsors

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

MGB Biopharma Limited

INDUSTRY